Daridorexant (Act-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder: a randomized, double-blind, placebo-controlled, active-reference phase 2 study

Sleep Medicine ◽

10.1016/j.sleep.2019.11.232 ◽

2019 ◽

Vol 64 ◽

pp. S85

Author(s):

Y. Dauvilliers ◽

G. Zammit ◽

I. Fietze ◽

D. Mayleben ◽

D. Sebök Kinter ◽

...

Keyword(s):

Receptor Antagonist ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Insomnia Disorder ◽

Phase 2 Study ◽

Reference Phase

Download Full-text

Daridorexant (ACT-541468), a new dual orexin receptor antagonist, for the treatment of insomnia disorder in the elderly: results from a randomized, double-blind, placebo-controlled, 5-period, 5-treatment crossover dose-response phase 2 study

Sleep Medicine ◽

10.1016/j.sleep.2019.11.1228 ◽

2019 ◽

Vol 64 ◽

pp. S437-S438

Author(s):

G. Zammit ◽

Y. Dauvilliers ◽

S. Pain ◽

D. Sebök Kinter ◽

D. Kunz

Keyword(s):

Receptor Antagonist ◽

Dose Response ◽

The Elderly ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Insomnia Disorder ◽

Phase 2 Study ◽

Response Phase

Download Full-text

0375 A Novel Dual Orexin Receptor Antagonist (ACT-541468) to Treat Insomnia: A Randomized, Double-Blind, Placebo-Controlled, Active-Reference Phase 2 Study

SLEEP ◽

10.1093/sleep/zsz067.374 ◽

2019 ◽

Vol 42 (Supplement_1) ◽

pp. A152-A153 ◽

Cited By ~ 1

Author(s):

Yves Dauvilliers ◽

Gary Zammit ◽

Ingo Fietze ◽

David Mayleben ◽

Dalma Seboek Kinter ◽

...

Keyword(s):

Receptor Antagonist ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Reference Phase

Download Full-text

0407 ACT-541468, A Dual Orexin Receptor Antagonist, For The Treatment Of Insomnia Disorder: A Randomized, Double-Blind, Placebo-Controlled, 5-Period, 5-Treatment Crossover Dose-Response Phase 2 Study In The Elderly

SLEEP ◽

10.1093/sleep/zsz067.406 ◽

2019 ◽

Vol 42 (Supplement_1) ◽

pp. A165-A165

Author(s):

Gary Zammit ◽

Yves Dauvilliers ◽

Scott Pain ◽

Dalma Seboek Kinter ◽

Dieter Kunz

Keyword(s):

Receptor Antagonist ◽

Dose Response ◽

The Elderly ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Insomnia Disorder ◽

Phase 2 Study ◽

Response Phase

Download Full-text

Faculty Opinions recommendation of P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725255169.793503497 ◽

2015 ◽

Author(s):

Brendan J Canning

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study

The Lancet ◽

10.1016/s0140-6736(14)61255-1 ◽

2015 ◽

Vol 385 (9974) ◽

pp. 1198-1205 ◽

Cited By ~ 232

Author(s):

Rayid Abdulqawi ◽

Rachel Dockry ◽

Kimberley Holt ◽

Gary Layton ◽

Bruce G McCarthy ◽

...

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725255169.793520450 ◽

2016 ◽

Author(s):

Geoffrey Burnstock

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734506216.793579336 ◽

2020 ◽

Author(s):

Nathalie Gaspar

Keyword(s):

Adult Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metastatic Osteosarcoma ◽

Phase 2 Study

Download Full-text

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

British Journal of Cancer ◽

10.1038/s41416-021-01356-3 ◽

2021 ◽

Author(s):

Ying Cheng ◽

Qiming Wang ◽

Kai Li ◽

Jianhua Shi ◽

Ying Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

Download Full-text

SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1836 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A617.2-A618

Author(s):

W. Kennedy ◽

P. Horn ◽

Z. Su ◽

K. Basu ◽

A. Herman ◽

...

Keyword(s):

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Lymphotoxin Alpha

Download Full-text

Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study

Inflammation Research ◽

10.1007/s00011-019-01218-y ◽

2019 ◽

Vol 68 (4) ◽

pp. 261-274 ◽

Cited By ~ 1

Author(s):

David L. Boyle ◽

Samuel E. DePrimo ◽

Cesar Calderon ◽

Dion Chen ◽

Paul J. Dunford ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Mechanism Of Action ◽

Active Rheumatoid Arthritis ◽

Phase 2 ◽

Histamine H4 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

H4 Receptor ◽

Orally Active

Download Full-text